Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 310
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479255/942-310-S50-4

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 310
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.H.2.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478116/942-310-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column E)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column E)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 45
-Paragraph 39
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477346/946-830-45-39

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(1)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column E)(Footnote 6)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Name:	us-gaap_InterestIncomeOperating
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Segment - Schedule of Segment Reporting Information by Segment (Details) - USD ($) $ in Thousands	3 Months Ended							9 Months Ended
	Sep. 30, 2026	Jun. 30, 2026	Mar. 31, 2026	Dec. 31, 2025	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2026	Sep. 30, 2025
Operating expenses:
Stock-based compensation expense	$ 3,492				$ 2,961			$ 9,321	$ 8,614
Interest and other expense	0				2			0	2
Reconciliation of loss:
Interest income	(1,505)				(804)			(3,516)	(2,813)
Adjustments and reconciling items	(1,505)				(804)			(3,516)	(2,813)
Net loss	17,846	$ 15,346	$ 15,157	$ 13,503	14,699	$ 15,390	$ 15,925	48,349	46,014
Clinical Research Segment [Member]
Operating expenses:
Direct program expense	9,945				6,824			24,149	22,187
Indirect program expense	558				459			1,754	1,417
Workforce salaries and benefits	4,074				4,202			12,768	12,952
Stock-based compensation expense	3,492				2,961			9,321	8,614
General corporate expenses	1,282				1,055			3,873	3,655
Interest and other expense					2				2
Reconciliation of loss:
Net loss	$ 19,351				$ 15,503			$ 51,865	$ 48,827